Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | SCN4A | P35499 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL10529320 | 0.93 | CYP1A2 (0.62) | CYP1A2MAPK1MEN1KMT2APPARG | |
| SCHEMBL21194 | 0.90 | CYP1A2 (0.60) | CYP1A2MAPK1MEN1KMT2AAR | |
| SCHEMBL93836 | 0.90 | CYP1A2 (0.60) | CYP1A2MAPK1MEN1KMT2AAR | |
| Succinic Acid SCHEMBL9777671 | 0.89 | CYP1A2 (0.57) | CYP1A2MAPK1MEN1KMT2APPARG | |
| Hydrochloric Acid SCHEMBL28891158 | 0.88 | CYP1A2 (0.58) | CYP1A2MAPK1MEN1KMT2AAR | |
| Maleic Acid SCHEMBL28861786 | 0.88 | CYP1A2 (0.56) | CYP1A2MAPK1MEN1KMT2APPARG | |
| Ethylene Glycol SCHEMBL16108602 | 0.86 | CYP1A2 (0.57) | CYP1A2MAPK1MEN1KMT2AAR | |
| SCHEMBL11554662 | 0.86 | LMNA (0.61) | CYP1A2MAPK1MEN1KMT2APPARG | |
| Benzoic Acid SCHEMBL28105551 | 0.83 | KMT2A (0.54) | CYP1A2MAPK1MEN1KMT2APPARG | |
| SCHEMBL5354587 | 0.82 | CYP1A2 (0.74) | CYP1A2MAPK1MEN1KMT2APPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12539297-B2 | Composition for inhibiting cancer metastasis and treating cancer | ONCOCROSS CO., LTD. (KR) | 2026-02-03 | — | — | US | claimed |
| US-12502371-B2 | Drug for treating and preventing dementia | NUMAN LABO LLC (JP) | 2025-12-23 | — | — | US | claimed |
| EP-3572080-B1 | COMPOSITION FOR INHIBITING CANCER METASTASIS AND TREATING CANCER | ONCOCROSS CO LTD (KR) | 2024-11-13 | — | — | EP | claimed |
| EP-4380599-A1 | COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF ACNE | FB Dermo S.r.l. (IT) | 2024-06-12 | — | — | EP | claimed |
| WO-2023012616-A1 | COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF ACNE | FB DERMO S.R.L. (IT) | 2023-02-09 | — | — | WO | claimed |
| US-20220362202-A1 | Drug For Treating And Preventing Dementia | NUMAN LABO LLC (JP) | 2022-11-17 | — | — | US | claimed |
| US-20220273642-A1 | COMPOSITION FOR INHIBITING CANCER METASTASIS AND TREATING CANCER | ONCOCROSS CO., LTD. (KR) | 2022-09-01 | — | — | US | claimed |
| EP-3618813-B1 | IMPROVED EXTENDED RELEASE HIGHLY LOADED DRUG COMPOSITIONS | LUBRIZOL ADVANCED MAT INC (US) | 2022-07-06 | — | — | EP | claimed |
| US-11364218-B2 | Method of treating or preventing mood disorders, mental disorders, and/or chronic fatigue syndrome | NUMAZAWA TOSHIHIKO (JP) | 2022-06-21 | — | — | US | claimed |
| US-11364237-B2 | Composition for inhibiting cancer metastasis and treating cancer | ONCOCROSS CO., LTD. (KR) | 2022-06-21 | — | — | US | claimed |
| WO-2007113856-A2 | DIRECTLY COMPRESSIBLE COMPOSITE FOR ORALLY DISINTEGRATING TABLETS | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2007-10-11 | — | — | WO | claimed |
| US-20070065463-A1 | Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions | AFGIN PHARMA LLC | 2007-03-22 | — | — | US | claimed |
| WO-2006130982-A1 | COMPOSITIONS AND METHODS FOR ENHANCING NITRIC OXIDE DELIVERY | UNIVERSITY OF MANITOBA (CA) | 2006-12-14 | — | — | WO | claimed |
| US-20050008702-A1 | Rupturing controlled release device having a preformed passageway | Osmotica Kereskedelmi és Szolgáltató KFT (HU) | 2005-01-13 | — | — | US | claimed |
| EP-1362585-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING A COX-II INHIBITOR AND A MUSCLE RELAXANT | Osmotica Corp. (VG) | 2003-11-19 | — | — | EP | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5700410-A | Method of manufacturing wax matrices | NIPPON SHINYAKU CO., LTD. (JP) | 1997-12-23 | — | — | US | claimed |
| US-4722938-A | COMBINED WITH NON-STEROIDAL ANTIINFLAMMATORY DRUG | ANALGESIC ASSOCIATES (US) | 1988-02-02 | — | — | US | claimed |
| EP-0205492-A1 | ANALGESIC, ANTI-INFLAMMATORY AND SKELETAL MUSCLE RELAXANT COMPOSITIONS | SUNSHINE, Abraham (US) | 1986-12-30 | — | — | EP | claimed |
| WO-1986003681-A1 | ANALGESIC, ANTI-INFLAMMATORY AND SKELETAL MUSCLE RELAXANT COMPOSITIONS | SUNSHINE ABRAHAM | 1986-07-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220273642-A1 | COMPOSITION FOR INHIBITING CANCER METASTASIS AND TREATING CANCER | MPHOSPH6, PLIN3, MIF | CYP1A2 3825/4885MAPK1 2805/4885MEN1 1949/4885 |
| US-12502371-B2 | Drug for treating and preventing dementia | ACHE, BCHE, CHRM3 | CYP1A2 1292/4885MAPK1 2742/4885MEN1 89/4885 |
| US-12539297-B2 | Composition for inhibiting cancer metastasis and treating cancer | CTSB, CTSE, CALCB | CYP1A2 3973/4885MAPK1 2115/4885MEN1 1566/4885 |
| US-20220362202-A1 | Drug For Treating And Preventing Dementia | ACHE, BCHE, CHRM3 | CYP1A2 1292/4885MAPK1 2742/4885MEN1 89/4885 |
| US-11364218-B2 | Method of treating or preventing mood disorders, mental disorders, and/or chronic fatigue syndrome | NR3C1, CRH, GRIN2C | CYP1A2 431/4885MAPK1 3174/4885MEN1 1926/4885 |
| US-11364237-B2 | Composition for inhibiting cancer metastasis and treating cancer | MKI67, CTSZ, CLSPN | CYP1A2 2634/4885MAPK1 2906/4885MEN1 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.